RT Journal Article
SR Electronic
T1 Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define diagnostic biosignatures for Parkinson’s Disease
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.18.22269096
DO 10.1101/2022.01.18.22269096
A1 Marco Hadisurya
A1 Li Li
A1 Kananart Kuwaranancharoen
A1 Xiaofeng Wu
A1 Zheng-Chi Lee
A1 Roy N. Alcalay
A1 Shalini Padmanabhan
A1 W. Andy Tao
A1 Anton Iliuk
YR 2022
UL http://medrxiv.org/content/early/2022/08/30/2022.01.18.22269096.abstract
AB Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene have been recognized as genetic risk factors for both familial and sporadic forms of Parkinson’s disease (PD). However, compared to cancer, overall lower genetic mutations contribute to the cause of PD, propelling the search for protein biomarkers for early detection of the disease. Utilizing 141 urine samples from four groups, healthy individuals (control), healthy individuals with G2019S mutation in the LRRK2 gene (non-manifesting carrier/NMC), PD individuals without G2019S mutation (idiopathic PD/iPD), and PD individuals with G2019S mutation (LRRK2 PD), we applied a proteomics strategy to determine potential diagnostic biomarkers for PD from urinary extracellular vesicles (EVs). After efficient isolation of urinary EVs through chemical affinity followed by mass spectrometric analyses of EV peptides and enriched phosphopeptides, we identified and quantified 4,480 unique proteins and 2,682 unique phosphoproteins. We detected multiple proteins and phosphoproteins elevated in PD EVs that are known to be involved in important PD pathways, in particular the autophagy pathway, as well as neuronal cell death, neuroinflammation, and formation of amyloid fibrils. Our data revealed that LRRK2 and its Rab substrates are altered but not significant PD biomarkers. We established two panels of proteins and phosphoproteins as novel candidates for disease and risk biomarkers, and substantiated using ROC, machine learning, clinical correlation, and in-depth network analysis. Several disease biomarkers were further validated in patients with PD using parallel reaction monitoring (PRM) and immunoassay for targeted quantitation. These findings demonstrate a general strategy of utilizing biofluid EV proteome/phosphoproteome as an outstanding and non-invasive source for a wide range of disease exploration.Competing Interest StatementThe authors declare a competing financial interest. A.I. and W.A.T. are principals at Tymora Analytical Operations, which developed EVtrap beads and commercialized PolyMAC enrichment kit.Funding StatementThis project was partially supported by The Michael J. Fox Foundation for Parkinsons Research Grant ID 17453 and NIH Grant ID 3RF1AG064250.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by Columbia University Irving Medical Center institutional review board (IRB) no. AAAP9604, and all participants signed an informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.